Nicotinamide N-methyltransferase as a marker for colorectal cancer

US7205118B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Michael Tacke · Munich, DE
• Peter Berndt · Basel, CH
• Marie-Luise Hagmann · Penzberg, DE
• Johann Karl · Peißenberg, DE
• Theresa Kott · Munich, DE
• Hanno Langen · Steinen, DE
• Stefan Palme · Bichl, DE
• Markus Roessler · Germering, DE
• Wolfgang Rollinger · Polling, DE
• Werner Zolg · Weilheim in Oberbayern, DE

Key dates

• Filing date: Jun 14, 2005
• Grant date: Apr 17, 2007
• Expiry date: Jun 14, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/48
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.